Cell Cancer-Fighting Trigger is Found
Posted on: Friday, 16 May 2008, 15:00 CDT
A Canadian scientist says he's found a way to trigger a protein that causes cells to fight cancer-causing agents, such as ultraviolet radiation.
University of Saskatchewan microbiology Professor Wei Xiao discovered how to trigger the protein combination called 9-1-1 in a finding that's been called a breakthrough in cancer research that could possibly lead to better cancer diagnosis through targeting defective genes.
Xiao and a team of graduate students found a process that can be used to activate the 9-1-1 protein complex, warning cells to stop dividing with damaged DNA that leads to cancer.
It has been known for many years that 9-1-1 was important, but scientists did not know how it was turned on, said Xiao.We figured out how 9-1-1 is actually activated when cells face carcinogens.
The next step toward developing diagnostic tools and drug treatments is to test whether Xiao's model, which used genes from baker's yeast that have counterparts in people, can apply to human cells as well.
The study appears in the journal Cell and will be presented this summer at Britain's Oxford University during the Gordon Research Conference on Mutagenesis.
Source: United Press International
Related Articles
- Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
- ZymoGenetics Presents Interim IL-21 Phase 2 Results in Renal Cell Cancer
- ZymoGenetics Initiates Phase II Renal Cell Cancer Trial
- ZymoGenetics Begins Phase 2 Trial in Renal Cell Cancer Evaluating IL-21 Combined With Nexavar(R)
- Cytokinetics Announces Initiation of Phase II Clinical Trial in Renal Cell Cancer and Phase I Clinical Trial in Pediatric Solid Tumors
- View Scientific Rationale for Novel Therapeutics in Lung Cancer, And the Results of Clinical Trials to Date Inside 'Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents'
- ZymoGenetics Begins Phase 1/2 Clinical Trial With IL-21 and Nexavar in Patients With Renal Cell Cancer
- Cancer Protein Heals Damaged Cord Cells
- Structure of Cell Membrane Protein Shown
- New In Vitro Study of GlycoGenesys' GCS-100LE Yields Promising Data in Chronic Lymphocytic Leukemia and Other B-Cell Cancers
 |
 |
User Comments (0)
RSS Feeds